Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)

Funding Opportunity RFA-AI-22-022 from the NIH Guide for Grants and Contracts. This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged.